MedTrace Logo

Caffeine and Hypoxia During Exercise in Males and Females

NCT05764018 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-08-12

No results posted yet for this study

Summary

Several high-altitude destinations recommend their visitors to avoid caffeine, theoretically due to the associated diuresis which could contribute to acute mountain sickness. There is however no direct evidence for this association. In fact, caffeine ingestion is known to improve exercise performance at sea level, and may therefore help mountaineers during expeditions.

Sport science research is largely conducted in male participants, and the findings from these studies are assumed to apply to the female population. Given the known sex differences in body composition, hormones, and other physiological factors, this may not be appropriate. It is therefore important to conduct research in women, to allow for female-specific recommendations.

Conditions

Interventions

DIETARY_SUPPLEMENT

Caffeine

Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise

OTHER

Hypoxia

Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.

OTHER

Placebo

Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.

OTHER

Normoxia

Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)

Sponsors & Collaborators

  • Jozef Stefan Institute

    lead OTHER

Principal Investigators

  • Tadej Debevec, PhD · University of Ljubljana

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2024-03-19
Completion
2024-03-19

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764018 on ClinicalTrials.gov